Rafferty Asset Management
CLDX icon

Rafferty Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Rafferty Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Sell
56,157
-8,893
-14% -$287K ﹤0.01% 632
2026
Q1 		$2.06M Sell
65,050
-49,180
-43% -$1.34M 0.01% 602
2025
Q4 		$3.1M Buy
114,230
+16,770
+17% +$442K 0.01% 552
2025
Q3 		$2.52M Buy
97,460
+25,902
+36% +$600K 0.01% 591
2025
Q2 		$1.46M Sell
71,558
-36,780
-34% -$716K ﹤0.01% 686
2025
Q1 		$1.97M Sell
108,338
-44,116
-29% -$986K 0.01% 584
2024
Q4 		$3.85M Buy
152,454
+61,464
+68% +$1.67M 0.01% 464
2024
Q3 		$3.09M Sell
90,990
-28,504
-24% -$1.09M 0.01% 531
2024
Q2 		$4.42M Sell
119,494
-71,921
-38% -$2.71M 0.02% 446
2024
Q1 		$8.03M Buy
191,415
+43,406
+29% +$1.78M 0.03% 345
2023
Q4 		$5.87M Sell
148,009
-16,781
-10% -$494K 0.02% 407
2023
Q3 		$4.54M Sell
164,790
-40,718
-20% -$1.28M 0.03% 402
2023
Q2 		$6.97M Buy
205,508
+59,772
+41% +$2.01M 0.04% 345
2023
Q1 		$5.24M Buy
145,736
+2,405
+2% +$104K 0.04% 374
2022
Q4 		$6.39M Sell
143,331
-64,362
-31% -$2.3M 0.05% 322
2022
Q3 		$5.84M Buy
207,693
+83,887
+68% +$2.57M 0.06% 300
2022
Q2 		$3.34M Sell
123,806
-32,446
-21% -$942K 0.03% 369
2022
Q1 		$5.32M Buy
156,252
+12,137
+8% +$388K 0.03% 377
2021
Q4 		$5.57M Buy
144,115
+86,971
+152% +$3.79M 0.03% 346
2021
Q3 		$3.08M Sell
57,144
-21,357
-27% -$1M 0.02% 462
2021
Q2 		$2.63M Sell
78,501
-42,558
-35% -$1.17M 0.02% 566
2021
Q1 		$2.49M Buy
121,059
+95,268
+369% +$2.19M 0.02% 567
2020
Q4 		$452K Buy
+25,791
New +$464K ﹤0.01% 706

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's CLDX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Celldex Therapeutics (CLDX) stake by 14% in Q2 2026, selling an estimated $287K and leaving 56,157 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #632.

Rafferty Asset Management first reported a position in CLDX in Q4 2020 and has held it in 23 quarters since. The position peaked at $8.03M in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Rafferty Asset Management held 56,157 shares of Celldex Therapeutics worth $2.09M as of Q2 2026.
  • Rafferty Asset Management sold 8,893 Celldex Therapeutics shares in Q2 2026, an estimated $287K.
  • Celldex Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #632 holding.
  • Rafferty Asset Management first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Rafferty Asset Management's Celldex Therapeutics position peaked at $8.03M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.